Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.57
+0.09 (1.06%)
At close: Apr 2, 2026, 4:00 PM EDT
8.51
-0.06 (-0.70%)
After-hours: Apr 2, 2026, 4:10 PM EDT
Xilio Therapeutics Analyst Ratings
Total Analysts
1
Consensus Rating
Buy
Price Target
$28.00
Upside
+226.72%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $28 | Buy | Initiates | $28 | +226.72% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $84 → $56 | Buy | Maintains | $84 → $56 | +553.44% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,043.52% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,043.52% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $280 → $140 | Buy | Maintains | $280 → $140 | +1,533.61% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $98 | Strong Buy | Initiates | $98 | +1,043.52% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $434 → $182 | Buy | Maintains | $434 → $182 | +2,023.69% | Nov 10, 2022 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $448 → $280 | Buy | Maintains | $448 → $280 | +3,167.21% | Aug 10, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $504 | Strong Buy | Initiates | $504 | +5,780.98% | Jan 10, 2022 |
| Raymond James | Raymond James | Buy Initiates $434 | Buy | Initiates | $434 | +4,964.18% | Nov 16, 2021 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $448 | Buy | Initiates | $448 | +5,127.54% | Nov 16, 2021 |